loading
전일 마감가:
$5.16
열려 있는:
$5.12
하루 거래량:
3.66M
Relative Volume:
2.53
시가총액:
$485.97M
수익:
$20.65M
순이익/손실:
$-192.65M
주가수익비율:
-1.8107
EPS:
-3.17
순현금흐름:
$-134.39M
1주 성능:
+0.53%
1개월 성능:
+26.15%
6개월 성능:
+11.89%
1년 성능:
-57.73%
1일 변동 폭
Value
$5.12
$5.76
1주일 범위
Value
$4.88
$5.76
52주 변동 폭
Value
$4.305
$19.34

Verve Therapeutics Inc Stock (VERV) Company Profile

Name
명칭
Verve Therapeutics Inc
Name
전화
(978) 501-3026
Name
주소
201 BROOKLINE AVENUE, BOSTON
Name
직원
255
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
VERV's Discussions on Twitter

VERV을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
VERV
Verve Therapeutics Inc
5.74 485.97M 20.65M -192.65M -134.39M -2.59
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-04-08 개시 H.C. Wainwright Buy
2023-04-13 개시 Canaccord Genuity Buy
2023-02-01 개시 Cantor Fitzgerald Neutral
2022-12-15 개시 Goldman Sell
2022-10-06 개시 Credit Suisse Neutral
2022-08-25 업그레이드 Stifel Hold → Buy
2022-06-17 개시 BMO Capital Markets Outperform
2022-02-18 개시 RBC Capital Mkts Outperform
2021-09-24 개시 Stifel Hold
2021-07-12 개시 Guggenheim Buy
2021-07-12 개시 JP Morgan Neutral
2021-07-12 개시 Jefferies Buy
2021-07-12 개시 William Blair Outperform
모두보기

Verve Therapeutics Inc 주식(VERV)의 최신 뉴스

pulisher
Dec 19, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc.VERV - The Eastern Progress Online

Dec 19, 2024
pulisher
Dec 19, 2024

Verve Therapeutics Inc Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsVERV - The Eastern Progress Online

Dec 19, 2024
pulisher
Dec 18, 2024

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit - The Eastern Progress Online

Dec 18, 2024
pulisher
Dec 18, 2024

2024-12-18 | Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing

Dec 18, 2024
pulisher
Dec 18, 2024

Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities Investigation - AccessWire

Dec 18, 2024
pulisher
Dec 17, 2024

Verve Therapeutics Slides As Insider Purchases Lose Another US$65k - Yahoo Finance

Dec 17, 2024
pulisher
Dec 16, 2024

Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - The Eastern Progress Online

Dec 16, 2024
pulisher
Dec 16, 2024

Charles Schwab Investment Management Inc. Increases Stake in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat

Dec 16, 2024
pulisher
Dec 15, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach Out - AccessWire

Dec 15, 2024
pulisher
Dec 15, 2024

2024-12-15 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach Out | NDAQ:VERV | Press Release - Stockhouse Publishing

Dec 15, 2024
pulisher
Dec 14, 2024

Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for InvestorsContact The Gross Law Firm - Victoria Advocate

Dec 14, 2024
pulisher
Dec 14, 2024

Verve Therapeutics' SWOT analysis: gene editing firm's stock faces hurdles - Investing.com India

Dec 14, 2024
pulisher
Dec 14, 2024

Verve Therapeutics' SWOT analysis: gene editing firm's stock faces hurdles By Investing.com - Investing.com Australia

Dec 14, 2024
pulisher
Dec 14, 2024

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - The Eastern Progress Online

Dec 14, 2024
pulisher
Dec 14, 2024

Verve Therapeutics, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before October 28, 2024 to Discuss Your RightsVERV - The Eastern Progress Online

Dec 14, 2024
pulisher
Dec 14, 2024

103,348 Shares in Verve Therapeutics, Inc. (NASDAQ:VERV) Purchased by XTX Topco Ltd - MarketBeat

Dec 14, 2024
pulisher
Dec 12, 2024

Pixalate Releases Q3 2024 EMEA Supply-Side Platform (SSP) Market Share Rankings for Connected TV (CTV), Mobile Apps, & Web: Magnite Leads CTV in Germany (65%) on Amazon Fire TV, Verve No. 1 on Mobile (57%) in Google Play Store - GlobeNewswire Inc.

Dec 12, 2024
pulisher
Dec 11, 2024

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - The Eastern Progress Online

Dec 11, 2024
pulisher
Dec 11, 2024

Shareholders that lost money on Verve Therapeutics, Inc.(VERV) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - The Eastern Progress Online

Dec 11, 2024
pulisher
Dec 11, 2024

Faruqi & Faruqi Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - The Eastern Progress Online

Dec 11, 2024
pulisher
Dec 11, 2024

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm - The Eastern Progress Online

Dec 11, 2024
pulisher
Dec 10, 2024

(VERV) On The My Stocks Page - Stock Traders Daily

Dec 10, 2024
pulisher
Dec 08, 2024

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth - Simply Wall St

Dec 08, 2024
pulisher
Dec 06, 2024

VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - The Eastern Progress Online

Dec 06, 2024
pulisher
Dec 06, 2024

Jacobs Levy Equity Management Inc. Increases Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat

Dec 06, 2024
pulisher
Dec 05, 2024

Redmile Group LLC Sells 80,040 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat

Dec 05, 2024
pulisher
Dec 03, 2024

Verve Therapeutics: Cutting-Edge Science But Highly Risky Stock - Seeking Alpha

Dec 03, 2024
pulisher
Dec 03, 2024

PDT Partners LLC Decreases Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat

Dec 03, 2024
pulisher
Dec 01, 2024

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. - GuruFocus.com

Dec 01, 2024

Verve Therapeutics Inc (VERV) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Verve Therapeutics Inc 주식 (VERV) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Kathiresan Sekar
Chief Executive Officer
Jun 28 '24
Option Exercise
2.87
30,000
86,100
351,128
Ashe Andrew D.
See Remarks
May 14 '24
Buy
6.26
76,000
475,760
342,509
Nickerson Joan
Chief Administrative Officer
Apr 02 '24
Sale
8.24
1,514
12,475
8,659
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
자본화:     |  볼륨(24시간):